Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LQDANASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia$12.48+0.4%$15.10$8.26▼$16.81$1.06B0.23946,983 shs252,586 shsUTHRUnited Therapeutics$287.48-1.5%$332.23$230.39▼$417.82$12.91B0.63449,805 shs66,834 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia-3.64%-15.73%-16.13%+0.24%-20.88%UTHRUnited Therapeutics-0.25%-5.37%-7.66%-19.49%+24.90%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLQDALiquidia2.1265 of 5 stars3.60.00.00.02.04.20.6UTHRUnited Therapeutics4.8506 of 5 stars3.34.00.04.63.13.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLQDALiquidia 3.11Buy$26.63113.43% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$388.2535.05% UpsideCurrent Analyst Ratings BreakdownLatest UTHR and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/20/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $34.003/20/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $25.003/20/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.002/27/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.001/9/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.001/8/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$415.00 ➝ $475.00(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLQDALiquidia$14.00M76.03N/AN/A$0.73 per share17.09UTHRUnited Therapeutics$2.88B4.49$17.29 per share16.63$127.35 per share2.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLQDALiquidia-$78.50M-$1.67N/AN/AN/A-765.38%-163.21%-67.14%5/12/2025 (Estimated)UTHRUnited Therapeutics$984.80M$24.6012.6310.460.9740.31%19.22%16.15%4/29/2025 (Estimated)Latest UTHR and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 million2/26/2025Q4 24UTHRUnited Therapeutics$6.10$6.19+$0.09$6.19$734.74 million$735.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLQDALiquidiaN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLQDALiquidiaN/A6.336.33UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLQDALiquidia64.54%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipLQDALiquidia30.10%UTHRUnited Therapeutics11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLQDALiquidia5085.30 million59.16 millionOptionableUTHRUnited Therapeutics98044.91 million39.33 millionOptionableUTHR and LQDA HeadlinesRecent News About These CompaniesAtika Capital Management LLC Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)April 8 at 5:56 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesApril 8 at 4:32 AM | insidertrades.comLiquidia: United Therapeutics Has The Last LaughApril 7 at 7:08 AM | seekingalpha.comIntegrated Quantitative Investments LLC Buys Shares of 1,110 United Therapeutics Co. (NASDAQ:UTHR)April 7 at 5:40 AM | marketbeat.comGeode Capital Management LLC Buys 44,277 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 7 at 4:28 AM | marketbeat.comBryce Point Capital LLC Purchases Shares of 3,522 United Therapeutics Co. (NASDAQ:UTHR)April 5 at 5:39 AM | marketbeat.comHeadlands Technologies LLC Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 4, 2025 | marketbeat.comFranklin Resources Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)April 4, 2025 | marketbeat.comAllstate Corp Acquires Shares of 1,176 United Therapeutics Co. (NASDAQ:UTHR)April 4, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by American Century Companies Inc.April 3, 2025 | marketbeat.comUnited Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to WorkApril 2, 2025 | finance.yahoo.comUnited Therapeutics Corp (UTHR) Recognized as a Top Employer by FortuneApril 2, 2025 | gurufocus.comIs United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now?April 2, 2025 | insidermonkey.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Alliancebernstein L.P.April 2, 2025 | marketbeat.comAxiom Investors LLC DE Increases Position in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comWellington Management Group LLP Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLCApril 2, 2025 | marketbeat.comCalifornia Public Employees Retirement System Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comSchroder Investment Management Group Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comNomura Asset Management Co. Ltd. Has $8.69 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comNorges Bank Takes Position in United Therapeutics Co. (NASDAQ:UTHR)April 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR and LQDA Company DescriptionsLiquidia NASDAQ:LQDA$12.48 +0.05 (+0.36%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.United Therapeutics NASDAQ:UTHR$287.48 -4.24 (-1.45%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
